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Granulocyte macrophage-colony stimulating factor (GM-CSF) is a hematopoietic growth factor, which stimulates the proliferation
of granulocytes and macrophages from bone marrow precursor cells. In autoimmune and inflammatory diseases, Th17 cells have
been considered as strong inducers of tissue inflammation. However, recent evidence indicates that GM-CSF has prominent
proinflammatory functions and that this growth factor (not IL-17) is critical for the pathogenicity of CD4+ T cells. Therefore,
the mechanism of GM-CSF-producing CD4+ T cell differentiation and the role of GM-CSF in the development of autoimmune
and inflammatory diseases are gaining increasing attention. This review summarizes the latest knowledge of GM-CSF and its
relationship with autoimmune and inflammatory diseases. The potential therapies targeting GM-CSF as well as their possible side
effects have also been addressed in this review.
1. Introduction
Granulocyte macrophage colony-stimulating factor (GM-
CSF) is a hematopoietic growth factor which was originally
recognized as a stimulator for the proliferation of granulo-
cytes and macrophages from bone marrow precursor cells
[1]. It has also been shown to promote the survival and
activation of mature myeloid cells and therefore contributes
to the maintenance of innate immune homeostasis [2].
Recent studies suggest that GM-CSF also has proinflamma-
tory functions and plays critical roles in the development of
autoimmune and inflammatory diseases, particularly inTh17
driven diseases [3, 4].
2. Biology of GM-CSF
2.1. Production of GM-CSF. GM-CSF is produced by a variety
of cells. Major sources of GM-CSF include activated T and B
cells, monocytes/macrophages, endothelial cells, fibroblasts,
and other sources such as neutrophils, eosinophils, epithelial
cells, mesothelial cells, chondrocytes, Paneth cells, and tumor
cells [5–7].The production ofGM-CSF in T cells is stimulated
by IL-1𝛽 and IL-23 in mice [3, 8], IL-1𝛽 and IL-12 in humans
[9], and also prostaglandin E2 [10]. In fibroblasts, endothelial
cells, chondrocytes, and smooth muscle cells, it is stimulated
by TNF-𝛼 and IL-1, and in macrophage/monocytes it is
stimulated by toll like receptors (TLRs) [5]. In lymphocytes,
the transcription factor nuclear factor of activated T cells
(NFAT) is reported to be required for the production of
GM-CSF [11, 12]. However, the production of GM-CSF can
be inhibited by IFN-𝛾 [13], IL-4 [14], IL-10 [15], and also
pharmacological agents such as cyclosporine A [16, 17] or
glucocorticoids [18].
2.2. GM-CSF Receptor and Signaling. The GM-CSF receptor
is expressed on myeloid cells and on some nonhaemopoietic
cells such as endothelial cells but not on T cells [19, 20].
The GM-CSF receptor is a heterodimer of an 𝛼-subunit
which binds GM-CSF with low affinity and a signaling 𝛽c-
subunit which is shared with the IL-3 and IL-5 receptors [21].
The 𝛽c-subunit constitutively associates with Janus kinase 2
(JAK2) and is tyrosine phosphorylated by it resulting in an
assembly of dodecameric signaling complex and initiation
of signaling [22]. The effects of GM-CSF are mediated in
a dose-dependent manner, by two 𝛽-chain residues: Ser585
and Tyr577 [23]. At low concentrations of GM-CSF, as in
normal healthy tissues, signaling occurs via Ser585 of the 𝛽-
chain, which leads to activation of the PI-3 kinase pathway
and results in myeloid cell survival. At high concentrations
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of GM-CSF, as at the site of inflammation, signaling via
Ser585 is extinguished and signaling occurs exclusively via
Tyr577 residue, which activates the Jak2/STAT5 pathway,
Ras/mitogen-activated protein kinase pathway and PI-3
kinase pathway, resulting in cell survival, proliferation, and
activation [23–26].
2.3. Action of GM-CSF. GM-CSF stimulates proliferation
and activation of macrophages, monocytes, neutrophils,
eosinophils, dendritic cells, and microglia [1, 27]. However,
sinceGM-CSF-deficientmice did not have a defect inmyeloid
cell development [28], a redundant role of GM-CSF in
myeloid cell development and differentiation under steady
state or homeostatic conditions is predicted. In addition to
its function as a hematopoietic growth factor, GM-CSF is now
recognized to have a variety of functions onmature hemopoi-
etic cells. GM-CSF enhances proinflammatory cytokine pro-
duction [29], antigen presentation [30, 31], and phagocytosis
[32–35] and promotes leukocyte chemotaxis and adhesion [5,
36–38]. GM-CSF deficient mice have increased susceptibility
to pulmonary [28, 39–41] and intestinal infections [42]
followed by systemic infection, indicating its importance in
maintaining immune homeostasis particularly in the lung
and intestines, which are constitutively exposed to pathogens.
2.3.1. Macrophages. GM-CSF stimulates the terminal dif-
ferentiation of macrophages and the acquisition of normal
immune functions via the transcription factor PU.1 [32].
GM-CSF also regulates phagocytosis of microbial pathogens
by macrophages through the upregulation of pathogen
associated molecular pattern (PAMP) receptors such as
C-type lectins including mannose receptors or Dectin-1,
scavenger receptors, integrins, or Fc𝛾 receptors via PU.1
[24, 32–34, 43]. Complement-dependent phagocytosis is also
enhanced by GM-CSF to control microbial pathogens [44].
GM-CSF also upregulates the expression of TLR2, TLR4,
or CD14 and boosts the production of proinflammatory
cytokines such as TNF, IL-6, IL-12p70, IL-23, or IL-1𝛽 [24,
32, 45, 46], leading to polarization of macrophages to the
M1- (classic-) like phenotype, thus, promoting Th1–Th17
responses [29, 47, 48] and contributing to tissue destruction
[49]. On the other hand, M-CSF polarizes macrophages to
the M2- (alternative-) like phenotype, which produces anti-
inflammatory cytokines such as IL-10 and CC-chemokine
ligand 2 (CCL2) and promotes tissue repair and remodeling
[49]. GM-CSF also regulates many functions in macrophages
including cell adhesion [32], pulmonary surfactant lipid and
protein catabolism [32], and several important antimicrobial
activities such as the production of reactive oxygen species
(ROS) or expression of antimicrobial enzymes [40].
2.3.2. Dendritic Cells (DCs). GM-CSF positively regulates
the development of migratory CD103+CD11b+ DCs [50]
but negatively regulates the development of resident CD8+
DCs [51]. GM-CSF also strongly induces the development
of inflammatory monocyte-derived DCs (moDCs) in vitro
[52]. However, it has not been well established whether GM-
CSF also regulates the development of moDCs in vivo. It
was reported that the number of moDCs was increased
in GM-CSF transgenic mice [53]. Furthermore, NF-𝜅B1-
dependent GM-CSF production in CD4 T cells was reported
to be required for the generation of moDCs in inflamma-
tory arthritis and antigen-induced peritonitis mouse models.
The number of moDCs was markedly reduced in draining
lymph nodes from GM-CSF−/− mice with inflammatory
arthritis or in the spleen of mice reconstituted with NF-
𝜅B1−/− CD4 T cells in acute peritonitis, demonstrating that
GM-CSF contributes to the differentiation of these cells
during inflammation in vivo [54]. On the other hand, GM-
CSF was shown to be dispensable for the differentiation of
moDCs, at least during acute infections, since the number
of moDCs was not decreased in GM-CSF−/− mice or GM-
CSF receptor deficient mice during acute infections [55,
56]. These data indicate that although GM-CSF strongly
regulates the production of moDCs in vitro and in vivo,
there may be another GM-CSF-independent pathway for the
development of moDCs [56]. Besides the regulation of DC
development, GM-CSF also upregulates cross-presentation,
bacterial uptake [53], or production of proinflammatory
cytokines such as IL-6 or IL-23 in resident DCs [57].
2.3.3. Neutrophils. In mature neutrophils, GM-CSF upregu-
lates the expression of the integrin CD11b, which increases
cellular adhesion and tissue entry [36]. GM-CSF also upreg-
ulates the antimicrobial functions of neutrophils, such as
phagocytosis or ROS production [58]. However, the expres-
sion of PU.1 in neutrophils of autoimmune pulmonary alveo-
lar proteinosis patients was normal, indicating that GM-CSF
is not involved in neutrophil differentiation [58].
2.3.4. B Cells. Among B cells, the innate-like B1 B cells
reside predominantly in serosal cavities such as the pleural
or peritoneal cavity. In response to microbial infection, B1a
B cells (a subset of B1 B cells) recognize bacteria via direct
TLR-dependent pathogen recognition and differentiate into
innate response activator (IRA) B cells, which produce GM-
CSF and also express theGM-CSF receptor [59, 60]. GM-CSF
acts on its receptor in an autocrine manner and induces IgM
production from B cells [59, 61]. Mixed chimeric mice with
B cell-restricted GM-CSF deficiency showed high bacterial
titer and morbidity after infection but did not show alveolar
proteinosis [60], indicating that B cell-derived GM-CSF is
necessary for protective IgM responses but dispensable for
surfactant clearance by alveolar macrophages. These data
indicate that the cellular source and location of GM-CSF is
important.
3. T Cell and GM-CSF
Although GM-CSF is widely expressed in both stromal and
hematopoietic cells, recent murine studies suggest that GM-
CSF from CD4+ T cells is essential in inflammatory mouse
models such as experimental autoimmune encephalomyelitis
(EAE), arthritis models such as collagen-induced arthritis
(CIA) or SKG-arthritis, interstitial lung disease in SKG mice
(SKG-ILD), peritonitis, or myocarditis [3, 4, 54, 57, 62–64].



































Figure 1: The differentiation of GM-CSF-producing CD4+ T cells
and cytokine networks. Activated macrophages and dendritic cells
(DCs) produce proinflammatory cytokines such as IL-23, IL-1𝛽, and
IL-6, which can promote the differentiation ofTh17 andTh1/17 cells,
leading to more GM-CSF production from Th1/17 cells. Increased
levels of GM-CSF upregulate further production of proinflamma-
tory cytokines frommacrophages/DCs, creating a positive feedback
loop. Activated macrophages/DCs also produce proinflammatory
cytokines, such as IL-1𝛽 and TNF𝛼, which stimulate the production
of GM-CSF from resident tissue cells, including endothelial cells,
epithelial cells, fibroblast, or chondrocytes.
AlthoughGM-CSF is known as one of theTh17 cytokines,Th1
cells and Th2 cells also express GM-CSF [64–67]. Moreover,
recent studies represent the existence of GM-CSF-producing
Th cells distinct from Th1, Th2, or Th17 cells [62, 64]
(Figure 1).
3.1. Th17 and Th1/17 Cells. Th17 cells have been shown to
be strong inducers of tissue inflammation and autoimmune
diseases. However, a number of studies determined that IL-
17 inhibition does not prevent but rather only ameliorates the
development of EAE [3, 4, 68, 69], CIA [70], SKG-arthritis,
or SKG-ILD [63] and that neutralizing IL-17 is a rather
unsatisfactory method for blocking Th17 mediated diseases
[71, 72]. Recently, it was reported that “classical” Th17 cells,
whichmainly produce IL-17, are not pathogenic and thatTh17
cells have high plasticity. As such, they instead differentiate
into highly pathogenic cells, called Th1/17 cells [73]. Th1/17
cells are characterized by their ability to coproduce IL-17,
IFN-𝛾, and GM-CSF and are identified by the coexpression
of T-bet, ROR𝛾t, and the chemokine receptors CXCR3 and
CCR6 [9, 74–78]. Human Th1/17 cells also express CD161, a
hallmark of Th17 progeny cells in humans that is induced
by ROR𝛾t [76, 79, 80]. Recent studies report that GM-CSF
is critical for the pathogenicity of Th17 cells [3, 4] and the
presence ofTh1/17 cells was observed at the inflammatory site
of inflammatory bowel disease (IBD),multiple sclerosis (MS),
and juvenile idiopathic arthritis (JIA) [76, 78, 81, 82].
In mice, IL-23 and IL-1𝛽 induce the production of GM-
CSF in T cells whereas IL-12 suppresses its expression [3,
4, 77, 83]. In contrast, in humans IL-1𝛽 renders Th17 cells
sensitive to IL-12 and both IL-1𝛽 and IL-12 promote the
differentiation of Th1/17 cells [9, 75, 81, 84, 85] (Figure 1). As
described in Section 2.3, GM-CSF induces the differentiation
of M1-like macrophages and upregulates the production of
proinflammatory cytokines such as IL-6, IL-12, IL-23, or IL-
1𝛽 from antigen presenting cells (APCs) [57]. This results in
further differentiation of Th17 and Th1/17 cells, thus creating
a positive feedback loop [3, 63].
Studies show that GM-CSF expression in CD4+ T cells is
not regulated by T-bet [3, 4] and ROR-responsive elements
are identified in the promoter of the gene encoding GM-
CSF [4]. Moreover, ectopic ROR𝛾t expression in CD4+ T
cells results in GM-CSF production, indicating that GM-
CSF production in Th1/17 cells is induced by ROR𝛾t [4].
Conversely, ROR𝛾t-deficient CD4+ T cells can produce GM-
CSF, indicating the existence of additional pathways to induce
GM-CSF production in CD4+ T cells [3].
3.2. Th-GM Cells. Recently, it was reported that IL-2- or
IL-7-activated STAT5 promotes the generation of GM-CSF-
producing CD4+ T cells with low or undetectable expression
of T-bet, GATA-3, ROR𝛾t transcripts. These cells repre-
sent a new distinct subset of Th cells, namely, Th-GM
[62, 64]. In humans, these Th-GM cells are identified as
CCR10+CCR4+CXCR3−CCR6−Thcells [64]. It was reported
that IL-7-activated STAT5directly bound to promoter regions
of the gene encoding GM-CSF [62]. The contribution of
IL-7 has been implicated in autoimmune diseases such as
multiple sclerosis or rheumatoid arthritis [86, 87], which also
suggests the contribution of Th-GM cells in these diseases.
High expression of IL-3, which is also involved in several
autoimmune diseases [88–90], was also reported in Th-GM
cells [62]. These cells were reported to be able to induce
a more severe experimental autoimmune encephalomyelitis
(EAE) than Th17 or Th1 cells [62, 64]. It is possible that
Th-GM cells provide GM-CSF to induce the expression of
IL-23 from APCs and cooperate with Th1/17 or Th1 cells to
exacerbate the development of inflammation.
3.3. Th1 Cells. Th1 cells are another source of GM-CSF
[4]. It was reported that Th1 cells also need GM-CSF to
mediate inflammation in the central nervous system (CNS)
[4]. However, the amount of GM-CSF produced by Th1 cells
is found to be consistently lower than that produced by Th17
cells, particularly during in vitro culture [65].
3.4. Th2 Cells. Th2 cells also produce GM-CSF [66, 67].
Although a positive correlation was found between GATA-3+
cells and GM-CSF+ cells in the nasal mucosa of patients with
allergic rhinitis [91], there is no study to our knowledge that
directly analyzes the role of GATA-3 in GM-CSF production.
Further investigation is therefore needed to elucidate the pre-
cise mechanism of GM-CSF production from CD4+ T cells
and their contribution to the development of autoimmune
and inflammatory diseases.
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4. GM-CSF in Autoimmune and
Inflammatory Diseases
4.1. GM-CSF in Central Nervous System. Multiple sclerosis
(MS) is a chronic inflammatory disease of the central
nervous system and is pathologically characterized by
demyelination and subsequent axonal degeneration. Past
studies have shown that CD4+ T cells play a critical role
in the development of MS and experimental autoimmune
encephalomyelitis (EAE), a widely used mouse model of
MS. It has been widely believed that Th17 cells are the main
encephalitogenic population in autoimmune inflammation
[92]; however, IL-17 has been found to be dispensable for the
development of EAE [4, 93]. On the other hand, GM-CSF
deficiency or neutralization of GM-CSF has been reported
to prevent the onset of EAE [94, 95]. The administration of
recombinant GM-CSF worsened the disease in EAE [94]
and elevated concentrations of GM-CSF have been reported
in the cerebrospinal fluid but not in the serum of patients
with relapsing-remitting or secondary progressive MS
[96, 97].
Recent findings show that GM-CSF is secreted by CNS-
infiltrating helper T cells and is essential for encephalito-
genicity in EAE [3, 4, 64]. GM-CSF induces the proliferation
and activation of microglial cells, which is required for the
onset of EAE [95, 98]. Activated microglial cells produce
highly neurotoxic substances such as ROS, nitrogen species,
glutamate, and TNF-𝛼 [99–102]. Furthermore, GM-CSF-
producing CD4+ T cells induce the differentiation of neuro-
toxicM1-like phenotype ofmicroglia [103] and upregulate the
production of proinflammatory mediators such as IL-1𝛽, IL-
6, and TNF𝛼, which contribute to myelin sheath damage, via
upregulation of TLR and CD14 expression [45].
Studies also show that GM-CSF is required for recruit-
ment of peripheral myeloid cells that contribute to blood-
brain barrier (BBB) and blood-spinal cord barrier (BSCB)
disruption and demyelization into the CNS [104, 105]. As we
described in Section 3.1, GM-CSF induces the polarization of
theM1-like macrophage phenotype and exacerbates the posi-
tive feedback loop ofTh17 andTh1/17 differentiation. Indeed,
an increased M1/M2 profile ratio of monocyte/macrophages
in the blood as well as in the CNS favors relapsing EAE and a
reduced M1/M2 ratio promotes an attenuated manifestation
of the disease [106].The ability of CNS-invadingmyeloid cells
to respond to CD4+ T cell-derived GM-CSF was shown to be
vital for the development of EAE [4].
Taken together, CNS-infiltrating CD4+ T cells initially
activate microglia and induce production of proinflamma-
tory cytokines, which contribute to myelin sheath damage
[95]. This initial neuroinflammation results in BBB destruc-
tion and leukocyte infiltration into the CNS parenchyma, fol-
lowed by restimulation of T cells by resident and infiltrating
APCs [107], leading to further APC activation.
These reports indicate that GM-CSF plays a central role
in MS and indicate that the inhibition of GM-CSF will be a
useful therapeutic strategy for MS. MOR103, a fully human
monoclonal antibody that binds humanGM-CSF, is currently
being tested in a phase Ib trial for MS [108] (Table 1). The
result of this and future trials are highly anticipated.
4.2. GM-CSF in Arthritis. Rheumatoid arthritis (RA) is a
systemic chronic autoimmune disease characterized by per-
sistent and erosive inflammatory polyarthritis. Recent studies
indicate that GM-CSF plays a central role in the pathogenesis
of RA as in MS, by activating or promoting differentiation
and survival of macrophages and neutrophils [109, 110]. The
concentrations of GM-CSFwere elevated in the synovial fluid
and plasma of RA patients [111, 112]. A case report showed
that the administration of recombinant GM-CSF exacerbated
the disease activity of RA [113]. The frequency of GM-CSF-
producing Th cells was significantly increased in synovial
fluid cells compared to peripheral blood mononuclear cells
(PBMCs) in patients with juvenile idiopathic arthritis (JIA)
and correlated with erythrocyte sedimentation rate (ESR)
levels [81, 114]. Synovial GM-CSF-producing T cells were
predominantly CD161 positive and coexpressed IFN-𝛾 but
not IL-17 [81], indicating that these cells are Th1/17 cells.
Alternatively, human synovial fibroblasts and chondrocytes
were also reported to produce GM-CSF in response to IL-1
and TNF stimulation [115, 116].
The contribution of GM-CSF in the development of
arthritis was also reported in several mouse models of
arthritis. In the collagen-induced arthritis (CIA)model, GM-
CSF deficient mice failed to develop arthritis [117], and
the administration of anti-GM-CSF neutralizing antibodies
ameliorated existing disease, prevented disease progression,
and reduced the concentrations of TNF and IL-1 in the
joints of treated mice [118]. On the other hand, GM-CSF
administration exacerbated arthritis in CIA [119].
In SKG mice, another model of autoimmune arthritis,
GM-CSF, upregulated proinflammatory cytokine production
such as IL-1𝛽 or IL-6 frommacrophages in a dose dependent
manner [63, 120].This in turn induced further differentiation
and expansion of IL-17-producing and GM-CSF-producing
CD4+ T cells [63]. The progression of arthritis in SKG mice
was inhibited by the neutralization of GM-CSF and slightly
by the neutralization of IL-17A [63], indicating that GM-CSF
plays a more critical role than IL-17A in SKG arthritis.
Mavrilimumab, a fully human anti-GM-CSF receptor 𝛼
antibody, is currently being developed and a phase II study
in RA patients reported significant efficacy with no serious
adverse events such as pulmonary alveolar proteinosis [121].
In this study of patients with active RA despite methotrexate
treatment, 55.7% of all participants treated with mavrili-
mumabmet the primary end point of achieving ≥1.2 decrease
from baseline in the disease activity score (DAS28-CRP) at
week 12. At the highest dose of mavrilimumab (100mg),
66.7% of subjects met the primary end point versus only
34.7% of the subjects in the placebo group [121].
MOR103, which is also being tested for MS, has shown
preliminary evidence of efficacy in a phase Ib/IIa trial for
patients with active RA [122]. Subjects receiving higher doses
of MOR103 (1.0 and 1.5mg/kg) showed significant improve-
ment in DAS28 scores and joint counts and significantly
higher European league against rheumatism response rates
than subjects receiving placebo [122]. Both mavrilimumab
andMOR103 showed rapid treatment responses and provided
evidence of clinical efficacy that support further clinical
investigation. Table 2 shows the results of clinical trials with
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Table 1: Clinical trials targeting GM-CSF.
Target Drug Type Indication Phase Status
GM-CSFR Mavrilimumab(CAM-3001) mAb RA II Completed

















Terminated, not published yet
Completed, not published yet
GM-CSF MORAb-022 mAb RA I On-going
GM-CSFR: GM-CSF receptor; mAb: monoclonal antibody; RA: rheumatoid arthritis; MS: multiple sclerosis.
Table 2: Effects of GM-CSF inhibitors in RA.









DAS28 change: −1.2 at week 12
41.0%, 61.0%, 53.8%, and 66.7% versus 34.7%
(𝑃 = 0.543, 0.011, 0.071, and 0.001)
ACR at week 12 100mg dose versus Placebo
ACR20: 69.2% versus 40.0% (𝑃 = 0.005)
ACR50: 30.8% versus 12.0% (𝑃 = 0.021)




0.3, 1.0, or 1.5mg/kg, IV
once a week for 4 weeks,
with follow-up to 16 weeks
𝑁 = 96
Significant differences in DAS28 change between placebo and MOR-103:
None, weeks 4 through 10, weeks 4 through 6
ACR at week 4, 1.0mg/kg versus placebo
ACR20: 68.2% versus 7.4% (𝑃 < 0.0001)
ACR50: 22.7% versus 3.7% (ns)
ACR70: 4.5% versus 0.0% (ns)
SC: subcutaneous injection; IV: intravenous injection; MTX: methotrexate; DAS28: 28-joint disease activity score; ACR20: American College of Rheumatology
20% response rate; ACR50: American College of Rheumatology 50% response rate; ACR70: American College of Rheumatology 70% response rate.
mavrilimumab and MOR103. A list of ongoing/completed
clinical trials targetingGM-CSF or its receptor is presented in
Table 1, withmore information available at ClinicalTrials.gov.
4.3. GM-CSF in Lung Disease
4.3.1. Pulmonary Alveolar Proteinosis. Pulmonary alveolar
proteinosis (PAP) is a rare syndrome characterized by the
accumulation of surfactant in pulmonary alveoli resulting in
varying degrees of respiratory insufficiency and myeloid cell
dysfunction leading to increased risk of infection [123, 124].
Several clinical forms of PAP have been identified includ-
ing autoimmune PAP caused by GM-CSF autoantibodies,
hereditary PAP caused by GM-CSF receptor mutations, and
secondary PAP associated with various underlying clinical
disorders which is presumed to cause this syndrome by
reducing alveolarmacrophage numbers or function [125]. It is
also reported that GM-CSF deficient mice develop abnormal
lung histology that is virtually indistinguishable from human
PAP [126].
Pulmonary surfactant is tightly regulated by balanced
production, secretion, reuptake, and catabolism within alve-
oli. GM-CSF regulates surfactant catabolism in alveolar
macrophages via PU.1 but does not regulate surfactant endo-
cytosis or uptake and catabolism of surfactant by alveolar
epithelial cells type II (AEC-II) [32, 127]. GM-CSF is also
required to stimulate numerous immune functions and ter-
minal differentiation of alveolarmacrophages [32] and induc-
tion of IgM production from B cells [60, 61]. Therefore, GM-
CSF deficient mice have high susceptibility to pulmonary
infections [28, 39–41] accompanied by systemic infections.
Based on the pathogenesis of PAP, several new therapeutic
approaches for treating autoimmune PAP targeting GM-CSF
are in clinical trials, including plasmapheresis [128], GM-CSF
administration [129, 130], and rituximab [131, 132].
4.3.2. Interstitial LungDisease. Themechanismof pulmonary
fibrosis in interstitial lung disease (ILD) has been studied
using Idiopathic pulmonary fibrosis (IPF) or a bleomycin-
induced mouse model of pulmonary fibrosis. Pulmonary
fibrosis in IPF is considered to be inflammation-independent
andmainly initiated by TGF-𝛽 produced by damaged epithe-
lial cells. In fact, anti-inflammatory therapies have little
benefit in IPF [133–135]. However, neutrophils, which pro-
duce ROS, MMPs, neutrophil elastase, or myeloperoxidase
and cause lung parenchymal and stromal cell injury [136–
138] or Th2 cytokines such as IL-4 or IL-13, which induce
fibroblast differentiation or extracellular matrix synthesis
[139, 140], have been reported to contribute to lung fibrosis
to some extent. Additionally, GM-CSF was reported to take
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part in the progress of pulmonary fibrosis. It was reported
that TNF𝛼-induced endothelin-1 (ET-1) upregulates GM-
CSF production from airway smooth muscle cells (ASMCs)
[141] and that GM-CSF was increased in the bronchoalveolar
lavage fluid (BALF) of patients with pulmonary fibrosis [142,
143]. GM-CSF stimulates macrophages to release profibrotic
cytokines and also induces fibrosis by direct stimulation of
airway smooth muscle cells [144, 145]. In fact, overexpression
of GM-CSF in the lungs led to severe neutrophil, eosinophil,
and macrophage infiltration and fibrotic reactions [145–147].
In contrast with idiopathic pulmonary fibrosis (IPF),
connective tissue disease-associated ILD (CTD-ILD) is often
characterized by a clearer response to immunosuppression,
indicating that autoimmune/inflammatory mechanisms play
a more significant and central role in the pathogenesis of
CTD-ILD [148, 149]. SKG mice, a model of autoimmune
arthritis, were reported to develop chronic-progressive inter-
stitial lung disease (ILD) that histologically resembles CTD-
ILD [63, 150, 151]. Recently, it was reported that ILD in
this mouse was characterized by massive infiltration of Th17
cells, GM-CSF-producing CD4+ T cells, and CD11b+Gr1+
neutrophils with fibrosis [63]. Naive SKG T cells were skewed
to differentiate into GM-CSF-producing cells. Furthermore,
GM-CSF secreted by T cells enhanced IL-6 and IL-1𝛽 produc-
tion by macrophages, which in turn enhanced differentiation
of IL-17A and/or GM-CSF-producing T cells and infiltration
of neutrophils into the lungs [63]. Neutralization of GM-CSF
completely blocked the development of this ILD, whereas
neutralization of IL-17A did not, showing that GM-CSF not
IL-17A is critical for the development of ILD in SKG mice
[63]. Importantly, neutralization ofGM-CSF ameliorated ILD
in SKG mice even after the onset of ILD [63], suggesting that
GM-CSF inhibition is a useful therapeutic strategy for CTD-
ILD. Mavrilimumab, a fully human anti-GM-CSF receptor 𝛼
antibody and MOR103, a fully human monoclonal anti-GM-
CSF antibody, are undergoing clinical trials in RA patients
[121, 122]. Further studies and future trials targeting GM-CSF
are awaited with interest.
4.4. GM-CSF in Intestine. Recent developments suggest that
the development of Crohn’s disease (CD) is caused by a
mucosal innate immunodeficiency with a variety of genetic
defects [152] and a dysfunction of granulocytes,macrophages,
and intestinal epithelial cells [153, 154]. In the intestine, GM-
CSF contributes to gut barrier function and resistance to
bacterial translocation by promoting the recruitment and
activation ofmonocytes/macrophages, neutrophils, andDCs.
This is accompanied by differentiation of Th1 and Th17 cells.
GM-CSF also promotes tissue repair via increased intesti-
nal epithelial cell proliferation and increased macrophages
as effectors of wound healing [155–157]. However, in CD
patients, the inherent defects in the mucosal barrier increase
the translocation of pathogens to the bowel tissue [152].
Moreover, increased levels of GM-CSF autoantibodies have
been reported in patients with ileal/ileocolonic CD, com-
pared with those with colon involvement only, ulcerative
colitis (UC) patients, or healthy controls. The high levels of
GM-CSF antibodies directly correlated with disease activity
and inversely correlated with neutrophil phagocytic activ-
ity [158]. Increased GM-CSF autoantibodies affect mucosal
integrity, bacterial killing and neutrophil migration, pro-
liferation, and survival [156]. GM-CSF deficient mice also
developed a more severe intestinal and systemic infection
after enteric infection [42] and were more susceptible to
acute dextran sodium sulfate- (DSS-) induced colitis [159].
Both severity of infection and colitis were largely prevented
by GM-CSF administration [160, 161]. On the other hand,
GM-CSF overexpression in the stomach leads to autoimmune
gastritis [162] and experimental peritonitis or intraperitoneal
LPS exposure in GM-CSF deficient mice resulted in blunted
proinflammatory responses and mortality [163]. The expres-
sion of GM-CSF at the mRNA level increases from the
stomach distally down through the colon, indicating that
gastrointestinal expression of GM-CSF expression parallels
bacterial localization [164]. These data indicate that the
threshold of GM-CSF levels between inflammation and
immune homeostasis can vary with tissue location or organs.
These findings indicate that administration of GM-CSF
could be beneficial for the treatment for CD patients. Initial
reports indicated that the administration of GM-CSF in
CD patients with moderate to severe disease activity had a
high rate of clinical response and remission with minimal
adverse effects [165, 166]. Moreover, a randomized phase II
clinical trial demonstrated that GM-CSF was significantly
more effective than placebo in obtaining a corticosteroid-
free clinical remission [167]. Conversely, a recent large
randomized trial found that it was no more effective than
placebo for induction of clinical remission or improvement
in active CD [168]. CD patients are known to have substantial
heterogeneity in pathogenic mechanisms and so GM-CSF as
a therapy may only be appropriate for a subgroup of patients.
Additionally, it is also important to verify the efficacy of GM-
CSF not only for the induction of remission but also for
the maintenance of remission. Therefore, further studies are
needed to elucidate the efficacy of GM-CSF as a treatment as
well as the appropriate patient character or phase of disease
to apply GM-CSF administration as a therapy.
4.5. GM-CSF in Allergic Disease. GM-CSF also was reported
to take part in Th2 response in allergic airway inflamma-
tion via activation of DCs [169–171]. In mouse models of
asthma, allergen-exposed epithelial cells release GM-CSF
which activates DCs and also prolongs eosinophil survival
[170, 172]. Consequently, GM-CSF neutralization reduced
allergic hyperresponsiveness in mice models [169, 170, 172].
KB003, a “humaneered” anti-GM-CSF antibody, is tested in
a phase II trial for severe asthma (Table 1). The result of this
trial is awaited.
5. Conclusion
GM-CSF plays pivotal roles not only in maintaining immune
homeostasis but also in exacerbating inflammatory reactions.
Recent findings indicate that GM-CSF inhibition will be
an attractive therapeutic strategy for many autoimmune
and inflammatory diseases. Studies also indicate that it is
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necessary to monitor possible side effects such as PAP or CD,
although GM-CSF inhibition has no demonstrated serious
adverse reactions so far, which is indicative of its wide
therapeutic index [63, 173, 174]. Further studies are necessary
to identify the molecular mechanisms that regulate GM-CSF
production and the role of GM-CSF in the development
of inflammatory diseases to devise preventive or curative
strategies for autoimmune and inflammatory diseases.
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